10-Q · October 30, 2025
Adtalem reported strong Q1 FY2026 results: consolidated revenue of $462,288 (in thousands) was up $44,888 (+10.8% YoY) and operating income rose to $85,477 (in thousands) up $15,239 (+21.7% YoY), driving diluted EPS of…
Earnings analysis · 10-Q
CVSA earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Covista Inc. recorded a Q3 fiscal 2026 revenue of $487.0 million, exceeding estimates, but reported lower EPS of $1.20, underperforming against expectations. The company raised its fiscal year revenue guidance to $1,930…
Read full summary
Covista Inc. recorded a Q3 fiscal 2026 revenue of $487.0 million, exceeding estimates, but reported lower EPS of $1.20, underperforming against expectations. The company raised its fiscal year revenue guidance to $1,930 - $1,945 million and adjusted EPS guidance to $7.95 - $8.15, reflecting strong demand despite segment challenges.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.2
- Segment
- Chamberlain: $197M, Walden: $186.6M, Medical and Veterinary: $103.5M
What stood out
-
Revenue Growth vs. Prior Periods
Revenue increased 4.5% or $21.0 million to $487.0 million in Q3 FY2026 compared to the prior year.
-
EPS Guidance Raised
Management increased EPS guidance to $7.95 - $8.15 from $7.80 - $8.00.
-
Segment Growth in Medical and Veterinary
Medical and Veterinary segment grew 8.9% or $8.4 million to $103.5 million in Q3 FY2026.
-
Improved Adjusted Earnings
Adjusted EPS rose 3.1% to $1.98, showcasing effective share repurchases.
-
Enrollment Increase at Walden
Walden's enrollment rose by 12.3% year-over-year, reflecting strong demand.
-
Cash Flow from Operations Up
Net cash from operating activities increased by $72.6 million to $346.4 million for the nine months ending March 31, 2026.
What to watch
-
Net Income Decline
Net income decreased 31.6% to $41.6 million compared to the prior year.
-
Operating Margin Pressure
Operating income grew minimally by 0.9% but underperformed due to rising operational costs.
-
Revenue Shift Impact
Walden revenue performance was complicated by a timing shift of $18M, reducing Q3 reported revenue.
Management's outlook
Management has revised revenue and EPS guidance upward due to strong demand.
Earlier filings 4
10-Q · May 8, 2025
Adtalem reported solid Q3 fiscal 2025 results with consolidated revenue of $466,055,000 (up $53,397,000, +12.9% YoY), meaningful operating leverage (operating income $90,509,000 vs $61,725,000) and diluted EPS of $1.59…
10-Q · January 30, 2025
Adtalem reported a strong second quarter (quarter ended Dec 31, 2024) with revenue of $447,729 (thousands), up $54,487 or 13.9% year-over-year, driven by growth at Chamberlain and Walden. Operating income expanded to…
10-Q · October 29, 2024
Adtalem reported a strong Q1 FY2025 with revenue of $417,400 (thousands), up $48,555 or 13.2% YoY, driven by increases at Chamberlain and Walden. Operating income rose to $70,238 (thousands) from $28,194 (thousands) a…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.